GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cardiff Oncology Inc (NAS:CRDF) » Definitions » E10

CRDF (Cardiff Oncology) E10 : $-31.72 (As of Mar. 2025)


View and export this data going back to 1997. Start your Free Trial

What is Cardiff Oncology E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Cardiff Oncology's adjusted earnings per share data for the three months ended in Mar. 2025 was $-0.200. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-31.72 for the trailing ten years ended in Mar. 2025.

During the past 3 years, the average E10 Growth Rate was 12.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Cardiff Oncology was 12.40% per year. The lowest was 6.60% per year. And the median was 9.50% per year.

As of today (2025-07-08), Cardiff Oncology's current stock price is $3.915. Cardiff Oncology's E10 for the quarter that ended in Mar. 2025 was $-31.72. Cardiff Oncology's Shiller PE Ratio of today is .


Cardiff Oncology E10 Historical Data

The historical data trend for Cardiff Oncology's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cardiff Oncology E10 Chart

Cardiff Oncology Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -50.94 -51.18 -46.48 -41.51 -34.46

Cardiff Oncology Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -40.68 -39.33 -36.82 -34.46 -31.72

Competitive Comparison of Cardiff Oncology's E10

For the Biotechnology subindustry, Cardiff Oncology's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cardiff Oncology's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cardiff Oncology's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Cardiff Oncology's Shiller PE Ratio falls into.


;
;

Cardiff Oncology E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Cardiff Oncology's adjusted earnings per share data for the three months ended in Mar. 2025 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=-0.2/134.9266*134.9266
=-0.200

Current CPI (Mar. 2025) = 134.9266.

Cardiff Oncology Quarterly Data

per share eps CPI Adj_EPS
201506 -29.520 100.684 -39.560
201509 -16.560 100.392 -22.257
201512 -18.720 99.792 -25.311
201603 -25.920 100.470 -34.809
201606 -24.480 101.688 -32.482
201609 -24.480 101.861 -32.427
201612 -24.480 101.863 -32.426
201703 -23.040 102.862 -30.222
201706 -18.720 103.349 -24.440
201709 -8.460 104.136 -10.961
201712 -4.320 104.011 -5.604
201803 -6.230 105.290 -7.984
201806 -5.270 106.317 -6.688
201809 -1.100 106.507 -1.394
201812 -1.090 105.998 -1.387
201903 -1.020 107.251 -1.283
201906 -0.760 108.070 -0.949
201909 -0.690 108.329 -0.859
201912 -0.510 108.420 -0.635
202003 -0.410 108.902 -0.508
202006 -0.510 108.767 -0.633
202009 -0.190 109.815 -0.233
202012 -0.180 109.897 -0.221
202103 -0.140 111.754 -0.169
202106 -0.170 114.631 -0.200
202109 -0.170 115.734 -0.198
202112 -0.230 117.630 -0.264
202203 -0.250 121.301 -0.278
202206 -0.240 125.017 -0.259
202209 -0.200 125.227 -0.215
202212 -0.200 125.222 -0.216
202303 -0.250 127.348 -0.265
202306 -0.250 128.729 -0.262
202309 -0.220 129.860 -0.229
202312 -0.210 129.419 -0.219
202403 -0.220 131.776 -0.225
202406 -0.260 132.554 -0.265
202409 -0.250 133.029 -0.254
202412 -0.210 133.157 -0.213
202503 -0.200 134.927 -0.200

Add all the adjusted EPS together and divide 10 will get our e10.


Cardiff Oncology  (NAS:CRDF) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Cardiff Oncology E10 Related Terms

Thank you for viewing the detailed overview of Cardiff Oncology's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Cardiff Oncology Business Description

Traded in Other Exchanges
Address
11055 Flintkote Avenue, San Diego, CA, USA, 92121
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.
Executives
James E. Levine officer: Chief Financial Officer 55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Renee P Tannenbaum director 9220 KIRBY DRIVE, SUITE 500, HOUSTON TX 77054
Gary W Pace director C/O RESMED INC, 14040 DANIELSON STREET, POWAY CA 92064-6857
Fairooz Kabbinavar officer: Chief Medical Officer C/O TOCAGEN INC., 4242 CAMPUS POINT COURT, STE. 500, SAN DIEGO CA 92121
Mark Erlander officer: Chief Scientific Officer C/O TROVAGENE, INC., 11055 FLINTKOTE AVENUE, SUITE A, SAN DIEGO CA 92121
Lale White director 310 GODDARD, SUITE 150, IRVINE CA 92618
James O Armitage director C/O TESARO, INC., 1000 WINTER ST., SUITE 3300, WALTHAM MA 02451
Tod Smeal officer: Chief Scientific Officer 11055 FLINTKOTE AVENUE, SA DIEGO CA 92121
Katherine L Ruffner officer: Chief Medical Officer 11055 FLINTKOTE AVENUE, SAN DIEGO CA 92121
Mani Mohindru director C/O CARA THERAPEUTICS, INC., 4 STAMFORD PLAZA, 107 ELM STREET, STAMFORD CT 06902
Rodney S Markin director C/O UNIVERSITY OF NEBR MEDICAL CENTER, 983135 NEBRASKA MEDICAL CENTER, OMAHA NE 68198-3135
Gary S Jacob director
Vicki Kelemen officer: Exec. VP and COO 11055 FLINTKOTE AVENUE, SAN DIEGO CA 92121
John P Brancaccio director C/O TAMIR BIOTECHNOLOGY, INC., 11 DEER PARK DRIVE, SUITE 204, MONMOUTH JUNCTION NJ 08852
Rajeev M. Shah 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116